Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$88.76 USD
-0.24 (-0.27%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $88.76 0.00 (0.00%) 5:48 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.76 USD
-0.24 (-0.27%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $88.76 0.00 (0.00%) 5:48 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
by Zacks Equity Research
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.
Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA
by Zacks Equity Research
Gilead's (GILD) regulatory application for breast cancer drug has been validated by the regulatory body in Europe.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $65.23 in the latest trading session, marking a +1.94% move from the prior day.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Sony, American Tower, Advanced Micro Devices and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Sony, American Tower, Advanced Micro Devices and Gilead Sciences
Top Stock Reports for UnitedHealth, Sony & American Tower
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Sony (SNE), and American Tower (AMT).
Roche (RHHBY) Stops Dosing in Huntington's Disease Study
by Zacks Equity Research
Roche (RHHBY) halts dosing in the phase III GENERATION HD1 study evaluating tominersen in manifest Huntington's disease following recommendation from an iDMC.
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
by Zacks Equity Research
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
Gilead Sciences (GILD) Stock Moves -0.53%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.08 in the latest trading session, marking a -0.53% move from the prior day.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments
by Zacks Equity Research
Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.
Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails
by Zacks Equity Research
Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.75 in the latest trading session, marking a +0.2% move from the prior day.
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
by Zacks Equity Research
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.
Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
by Zacks Equity Research
FATE reports a wider Q4 loss on increased R&D expenses.
The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Deere, T-Mobile US and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Deere, T-Mobile US and Gilead Sciences
Top Analyst Reports for Apple, P&G, Deere & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Procter & Gamble (PG), and Deere (DE).
Stock Market News for Feb 17, 2021
by Zacks Equity Research
The Dow booked a second straight record high on Tuesday with progress in Biden¿¿¿s $1.9 trillion coronavirus relief package and data showing COVID-19 cases dropping.
Gilead (GILD) & Galapagos Discontinue Development of IPF Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.
TEVA Stock Declines Despite Q4 Earnings and Sales Beat
by Zacks Equity Research
TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.